198 related articles for article (PubMed ID: 24842803)
1. Neurotransmitter-based strategies for the treatment of cognitive dysfunction in Down syndrome.
Das D; Phillips C; Hsieh W; Sumanth K; Dang V; Salehi A
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Oct; 54():140-8. PubMed ID: 24842803
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics: the neglected key to minimize learning and memory deficits in Down syndrome.
Dekker AD; De Deyn PP; Rots MG
Neurosci Biobehav Rev; 2014 Sep; 45():72-84. PubMed ID: 24858130
[TBL] [Abstract][Full Text] [Related]
3. Neurobiological elements of cognitive dysfunction in down syndrome: exploring the role of APP.
Millan Sanchez M; Heyn SN; Das D; Moghadam S; Martin KJ; Salehi A
Biol Psychiatry; 2012 Mar; 71(5):403-9. PubMed ID: 21945306
[TBL] [Abstract][Full Text] [Related]
4. Down syndrome: genes, model systems, and progress towards pharmacotherapies and clinical trials for cognitive deficits.
Busciglio J; Capone G; O'Bryan J; Gardiner KJ
Cytogenet Genome Res; 2013; 141(4):260-71. PubMed ID: 24008277
[TBL] [Abstract][Full Text] [Related]
5. From abnormal hippocampal synaptic plasticity in down syndrome mouse models to cognitive disability in down syndrome.
Cramer N; Galdzicki Z
Neural Plast; 2012; 2012():101542. PubMed ID: 22848844
[TBL] [Abstract][Full Text] [Related]
6. Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships.
Belichenko PV; Kleschevnikov AM; Salehi A; Epstein CJ; Mobley WC
J Comp Neurol; 2007 Oct; 504(4):329-45. PubMed ID: 17663443
[TBL] [Abstract][Full Text] [Related]
7. Mental retardation and associated neurological dysfunctions in Down syndrome: a consequence of dysregulation in critical chromosome 21 genes and associated molecular pathways.
Rachidi M; Lopes C
Eur J Paediatr Neurol; 2008 May; 12(3):168-82. PubMed ID: 17933568
[TBL] [Abstract][Full Text] [Related]
8. Rescue of synaptic failure and alleviation of learning and memory impairments in a trisomic mouse model of down syndrome.
Blanchard J; Bolognin S; Chohan MO; Rabe A; Iqbal K; Grundke-Iqbal I
J Neuropathol Exp Neurol; 2011 Dec; 70(12):1070-9. PubMed ID: 22082658
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.
Gardiner KJ
Drug Des Devel Ther; 2015; 9():103-25. PubMed ID: 25552901
[TBL] [Abstract][Full Text] [Related]
10. Down syndrome--recent progress and future prospects.
Wiseman FK; Alford KA; Tybulewicz VL; Fisher EM
Hum Mol Genet; 2009 Apr; 18(R1):R75-83. PubMed ID: 19297404
[TBL] [Abstract][Full Text] [Related]
11. Mental retardation in Down syndrome: from gene dosage imbalance to molecular and cellular mechanisms.
Rachidi M; Lopes C
Neurosci Res; 2007 Dec; 59(4):349-69. PubMed ID: 17897742
[TBL] [Abstract][Full Text] [Related]
12. Aneuploidy: from a physiological mechanism of variance to Down syndrome.
Dierssen M; Herault Y; Estivill X
Physiol Rev; 2009 Jul; 89(3):887-920. PubMed ID: 19584316
[TBL] [Abstract][Full Text] [Related]
13. Hippocampal network alterations in Alzheimer's disease and Down syndrome: from structure to therapy.
Sanchez MM; Moghadam S; Naik P; Martin KJ; Salehi A
J Alzheimers Dis; 2011; 26 Suppl 3():29-47. PubMed ID: 21971449
[TBL] [Abstract][Full Text] [Related]
14. Dosage-dependent over-expression of genes in the trisomic region of Ts1Cje mouse model for Down syndrome.
Amano K; Sago H; Uchikawa C; Suzuki T; Kotliarova SE; Nukina N; Epstein CJ; Yamakawa K
Hum Mol Genet; 2004 Jul; 13(13):1333-40. PubMed ID: 15138197
[TBL] [Abstract][Full Text] [Related]
15. Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome.
Altafaj X; Martín ED; Ortiz-Abalia J; Valderrama A; Lao-Peregrín C; Dierssen M; Fillat C
Neurobiol Dis; 2013 Apr; 52():117-27. PubMed ID: 23220201
[TBL] [Abstract][Full Text] [Related]
16. Rescuing Over-activated Microglia Restores Cognitive Performance in Juvenile Animals of the Dp(16) Mouse Model of Down Syndrome.
Pinto B; Morelli G; Rastogi M; Savardi A; Fumagalli A; Petretto A; Bartolucci M; Varea E; Catelani T; Contestabile A; Perlini LE; Cancedda L
Neuron; 2020 Dec; 108(5):887-904.e12. PubMed ID: 33027640
[TBL] [Abstract][Full Text] [Related]
17. Chronic melatonin treatment rescues electrophysiological and neuromorphological deficits in a mouse model of Down syndrome.
Corrales A; Vidal R; García S; Vidal V; Martínez P; García E; Flórez J; Sanchez-Barceló EJ; Martínez-Cué C; Rueda N
J Pineal Res; 2014 Jan; 56(1):51-61. PubMed ID: 24147912
[TBL] [Abstract][Full Text] [Related]
18. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
De la Torre R; De Sola S; Pons M; Duchon A; de Lagran MM; Farré M; Fitó M; Benejam B; Langohr K; Rodriguez J; Pujadas M; Bizot JC; Cuenca A; Janel N; Catuara S; Covas MI; Blehaut H; Herault Y; Delabar JM; Dierssen M
Mol Nutr Food Res; 2014 Feb; 58(2):278-88. PubMed ID: 24039182
[TBL] [Abstract][Full Text] [Related]
19. Communication breaks-Down: from neurodevelopment defects to cognitive disabilities in Down syndrome.
Contestabile A; Benfenati F; Gasparini L
Prog Neurobiol; 2010 May; 91(1):1-22. PubMed ID: 20097253
[TBL] [Abstract][Full Text] [Related]
20. Mouse models of cognitive disabilities in trisomy 21 (Down syndrome).
Roubertoux PL; Carlier M
Am J Med Genet C Semin Med Genet; 2010 Nov; 154C(4):400-16. PubMed ID: 20981769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
